Here, we chose MET, a tyrosine kinase receptor of HGF, as a treatment target because various cancers, including OC, are characterized by an alternating MET expression, which is generally associated with a poor prognosis and aggressive phenotypes [29]. This evidence concerns the gene HGF and cancer.